Rutgers deploys Virtuix Omni One for AI-enhanced neurodivergent therapy research
Virtuix Holdings Inc. announced that Rutgers University has deployed its Omni One omni-directional treadmill platform at WINLAB for research into AI-assisted neurodivergent therapy and immersive behavioral analytics, including autism therapy for children. This collaboration expands Virtuix's applications beyond its traditional consumer and defense markets, exploring how full-body movement and AI interaction can enhance therapeutic engagement. The global autism spectrum disorder treatment market is projected to grow from approximately $9.2 billion in 2026 to over $18 billion by 2034, highlighting the increasing demand for such innovative solutions.
Key Highlights
- Rutgers University deployed Virtuix Omni One for AI-assisted neurodivergent therapy research.
- Collaboration explores movement-centered XR and AI-enhanced behavioral therapy applications.
- Broadens Virtuix’s applications beyond traditional consumer and defense end markets.
- Global ASD treatment market projected to grow from $9.2B (2026) to $18B (2034).
- Follows Omni One deployment to Florida Gulf Coast University for rehabilitation.
- The ASD market is expected to grow at a CAGR of 9% through 2034.
Price Impact
More from VTIX
Virtuix Holdings Amends Warrants, Exercise Price Reduced to $3.00
Virtuix FY26 Revenue +18% to $4.3M; Gross Margin 25%; Launches Omni One for Quest
Virtuix Holdings Completes Nasdaq Direct Listing, Secures $8M Initial Equity Advance